The stock of United Therapeutics Corp (UTHR) has gone up by 7.65% for the week, with a 11.62% rise in the past month and a 18.79% rise in the past quarter. The volatility ratio for the week is 3.41%, and the volatility levels for the past 30 days are 2.59% for UTHR. The simple moving average for the past 20 days is 8.45% for UTHR’s stock, with a 11.04% simple moving average for the past 200 days.
Is It Worth Investing in United Therapeutics Corp (NASDAQ: UTHR) Right Now?
The price-to-earnings ratio for United Therapeutics Corp (NASDAQ: UTHR) is 12.86x, which is above its average ratio. Moreover, the 36-month beta value for UTHR is 0.54. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 6 as “hold,” and 4 as “sell.”
The public float for UTHR is 40.89M and currently, short sellers hold a 10.56% of that float. On May 02, 2024, UTHR’s average trading volume was 477.18K shares.
UTHR) stock’s latest price update
United Therapeutics Corp (NASDAQ: UTHR)’s stock price has gone rise by 8.88 in comparison to its previous close of 234.33, however, the company has experienced a 7.65% increase in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-01 that Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Analysts’ Opinion of UTHR
Many brokerage firms have already submitted their reports for UTHR stocks, with Goldman repeating the rating for UTHR by listing it as a “Neutral.” The predicted price for UTHR in the upcoming period, according to Goldman is $215 based on the research report published on February 12, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see UTHR reach a price target of $330. The rating they have provided for UTHR stocks is “Outperform” according to the report published on February 05th, 2024.
Wells Fargo gave a rating of “Overweight” to UTHR, setting the target price at $309 in the report published on December 08th of the previous year.
UTHR Trading at 8.89% from the 50-Day Moving Average
After a stumble in the market that brought UTHR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.45% of loss for the given period.
Volatility was left at 2.59%, however, over the last 30 days, the volatility rate increased by 3.41%, as shares surge +10.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.14% upper at present.
During the last 5 trading sessions, UTHR rose by +7.65%, which changed the moving average for the period of 200-days by +8.91% in comparison to the 20-day moving average, which settled at $236.46. In addition, United Therapeutics Corp saw 16.03% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at UTHR starting from ROTHBLATT MARTINE A, who sale 3,600 shares at the price of $235.35 back on Apr 30 ’24. After this action, ROTHBLATT MARTINE A now owns 130 shares of United Therapeutics Corp, valued at $847,277 using the latest closing price.
ROTHBLATT MARTINE A, the CHAIRPERSON & CEO of United Therapeutics Corp, sale 3,600 shares at $238.64 during a trade that took place back on Apr 29 ’24, which means that ROTHBLATT MARTINE A is holding 130 shares at $859,088 based on the most recent closing price.
Stock Fundamentals for UTHR
Current profitability levels for the company are sitting at:
- 0.5 for the present operating margin
- 0.89 for the gross margin
The net margin for United Therapeutics Corp stands at 0.42. The total capital return value is set at 0.22. Equity return is now at value 18.27, with 14.81 for asset returns.
Based on United Therapeutics Corp (UTHR), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 4.9. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 39.03.
Currently, EBITDA for the company is 1.39 billion with net debt to EBITDA at -0.75. When we switch over and look at the enterprise to sales, we see a ratio of 4.11. The receivables turnover for the company is 8.13for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.41.
Conclusion
To wrap up, the performance of United Therapeutics Corp (UTHR) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
